Treatment for newly diagnosed low-risk pediatric B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 to 17 years old
- Newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL)
- Classified as low risk by the doctor
- No other serious health conditions like heart disease or immune problems
- No prior chemotherapy or radiation in the last 3 months (except emergency treatment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Hear when a new Childhood Leukemia, Acute Lymphoblastic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.